A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1612-1615

  Cermak, Jaroslav ^a   Jonasova, Anna ^b   Vondrakova, Jana ^c   Cervinek, Libor ^d   Belohlavkova, Petra ^e   Neuwirtova, Radana ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Deferasirox, Chelation; Deferiprone; Myelodysplasia; Side effects; Toxicity

Indexed keywords

DEFERASIROX; DEFERIPRONE; FERRITIN;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION;

EID: 84888136815     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.021     Document Type: Article

References (27)

1. Bowen D.T., Hellström-Lindberg E. Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy. Leuk Res 2001, 25:19-21.
2. Cermak J., Kacirkova P., Mikulenkova D., Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009, 33:1469-1474.
3. Marx J.J.M., van Asbeck B.S. Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol 1996, 95:49-62.
4. Gattermann N., Rachmilewitz E. Iron overload in MDS-pathophysiology, diagnosis and complications. Ann Hematol 2011, 80:1-10.
5. Kontoghiorghes G.J., Aldouri M.A., Sheppard L., et al. 1-2-dimethyl-3-hydroxypyrid-4-one an orally active chelator for treatment of iron overload. Lancet 1987, 329:1294-1295.
6. Olivieri N.F., Brittenham G.M., Matsui D., et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995, 332:918-922.
7. Al-Refaie F.N., Wonke B., Hoffbrand A.V. Deferiprone-associated myelotoxicity. Eur J Haematol 1994, 53:298-301.
8. Jaeger M., Aul C., Söhngen D., et al. Iron overload in polytransfused patients with MDS: use of L1 for oral iron chelation. Drugs Today 1992, 28(Suppl. A):143-147.
9. Porter J., Galanello R., Saglio G., et al. Relative response of patiens with myelodysplastic syndromes and other transfusion- dependent anemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008, 80:168-176.
10. Gattermann N., Finelli C., Della Porta M., et al. Deferasirox in ironoverloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34:1143-1150.
11. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. Greenberg P.L., Tuechler H., Schanz J., et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
13. Malcovati L., Porta M., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
14. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis nad therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187-200.
15. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
16. Steensma D.P. The relevance of iron overload and the appropriateness of iron chelation therapy for patiens with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep 2011, 6:136-144.
17. Rose C., Brechignac S., Vassilief D., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients?. A multicenter study by the GFM. Leuk Res 2010, 34:864-870.
18. Sanz G., Nomdedeu B., Such E., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008, 112:640. ASH (Annual Meeting Abstracts).
19. Leitch H. Controversies surrounding chelation therapy for MDS. Blood Rev 2011, 25:17-31.
20. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
21. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia: new data, new questions. Blood 2008, 107:3436-3441.
22. Anderson L.J., Westwood M.A., Holden S., et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004, 127:348-355.
23. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2005, 107:3455-3462.
24. Zachariah M., Tony S., Bashir W., et al. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single center experience. Pediatr Hematol Oncol 2013, 30:104-112.
25. Gattermann N., Finelli C., Della Porta M., et al. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica 2012, 97:1364-1371.
26. Cermak J. Erythropoietin administration may potentiate mobilization of iron stores in patients on iron chelation therapy. Hemoglobin 2006, 30:105-112.
27. Ganz T., Nemeth E. Iron metabolism: interaction with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med 2012, 2:a011668.